Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01180621
Other study ID # PCIRN RT-07
Secondary ID
Status Completed
Phase Phase 2
First received August 11, 2010
Last updated June 21, 2011
Start date September 2010
Est. completion date April 2011

Study information

Verified date June 2011
Source Dalhousie University
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

The seasonal influenza vaccination program for 2010-2011 will be the first to follow the H1N1 pandemic of 2009. Many children either had the H1N1 infection or the adjuvanted H1N1 vaccine. Both H1N1 infection and adjuvanted vaccine produced strong immune responses which could last for some time.

The seasonal influenza vaccine for this fall will be a trivalent inactivated product (regular seasonal influenza vaccine)once again, without adjuvant. It will contain 3 strains of killed, split-apart viruses that might circulate this winter, including the H1N1 pandemic strain. It is theoretically possible that giving the H1N1-containing seasonal vaccine to people who still have some immunity to H1N1 virus could result in more frequent side-effects. However, there is no good evidence that pre-existing immunity to a strain in the vaccine does increase side-effects. In short, there could be nothing out of the ordinary this fall but it would be prudent to check this before public flu vaccination programs begin.


Description:

This study will assess the safety of seasonal influenza vaccination in children who received one or two doses of the adjuvanted H1N1 vaccine last year. It will also measure residual immunity to the H1N1 virus and immune responses to the seasonal vaccine. It will be carried out before the new vaccine is released for general use so that we have an accurate picture of vaccine safety and responses for other Canadians.

A total of 200 children (50 at each site) 12-59 month olds, are being asked to participate in this study. A research nurse will conduct a telephone screening with potential participants to determine if they are eligible for the study. Volunteers must have had one or two doses of the adjuvanted H1N1 vaccine before January 31, 2010. To eligible participants do not need a previous years seasonal flu vaccine(TIV)however, this will be recorded.

The study involves 1-2 vaccination visits 28 days apart. Those children who have not received a previous dose of TIV will receive a second dose at visit # 2. After each vaccination, there will be contacts 1 and 7 days later for a description of any symptoms experienced. A blood sample will be requested at at each study visit (2 or 3 visits depending on previous TIV history) to measure immune responses to the seasonal vaccine.

The study will take 21-42 days to complete, depending upon whether or not the child received a previous dose of seasonal TIV vaccination. The 4 study sites are in Vancouver, Calgary, Montreal and Halifax.

Each subject's parent will be asked to keep daily notes of any changes at the injection site (pain, redness, swelling) and any general symptoms (such as irritability, drowsiness, decreased appetite, sleep disturbance,sweating and shivering, including your axilla or rectal temperature, for 7 days after each vaccination. Major health changes will be assessed for 21 days post vaccination.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date April 2011
Est. primary completion date October 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 12 Months to 59 Months
Eligibility Inclusion Criteria:

- Written informed consent provided for the subject by a parent or legal guardian.

- Subjects whose parents the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, record safety observations, able to converse with study personnel including by telephone).

- Age 12-59 months at Visit 1, male or female

- Receipt of one or two doses of Arepanrix (adjuvanted H1N12009 vaccine, GlaxoSmithKline (GSK)) in 2009 documented by written record or attested by a confident personal recollection (window for vaccination will be 1 October 2009 to January 31, 2010).

Exclusion Criteria:

- Systemic hypersensitivity to hens' eggs or to any other Fluviral S/F vaccine component such as thimerosal

- History of a life-threatening reaction to any influenza vaccine

- Receipt of Arepanrix after January 31st , 2010

- Receipt of non-study TIV (Trivalent Influenza Vaccine)for the 2010-2011 season

- Receipt of any live vaccine within 4 weeks or inactivated vaccine within one week of study entry or planned administration of any non-study vaccines during the study period

- Thrombocytopenia or any bleeding disorder that contraindicates IM injection or blood collection

- Receipt of blood or any blood-derived products within the past 3 months

- Chronic illness at a stage that could interfere with trial participation (stable health conditions are acceptable, such as diabetes, lung disease, heart conditions etc)

- Immune compromise as a result of a medical condition, transplantation or immunosuppressive medication, not including topical or aerosol medications

- Participation in any other research study involving a non-approved drug or medical device

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
Fluviral
0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age

Locations

Country Name City State
Canada ACHIEVE Research, Alberta Children's Hospital Calgary Alberta
Canada Candian Center for Vaccinology, Dalhousie University Halifax Nova Scotia
Canada McGill University Health Centre - Vaccine Study Centre Montreal Quebec
Canada Vaccine Evaluation Center Vancouver British Columbia

Sponsors (4)

Lead Sponsor Collaborator
Dalhousie University Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, IWK Health Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the safety of 2010-2011 seasonal trivalent influenza vaccine (TIV) Assessing reactogenicity on days 1-6 following TIV administration. 7 days Yes
Secondary To measure immune response to each component of TIV. Determining if there is a relationship between pre-TIV influenza haemagglutinin titers (ie, 6 to 10 months after receipt of adjuvanted vaccine), post TIV titers, and reactogenicity following TIV receipt. 42 days Yes
See also
  Status Clinical Trial Phase
Completed NCT01209780 - Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age Phase 3
Completed NCT01206686 - The Effect of Time-Slot Scheduling on Flu Vaccination Rates N/A
Recruiting NCT06049927 - A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months Phase 3
Completed NCT04133584 - The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine Phase 4
Completed NCT05566639 - A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older Phase 3
Completed NCT01072799 - Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine Phase 2
Completed NCT01207232 - The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates N/A
Completed NCT00957996 - Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Phase 3
Completed NCT04997239 - A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old Phase 4
Completed NCT05512494 - Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated Phase 4
Terminated NCT00958776 - A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza Phase 3
Completed NCT01011582 - Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza N/A
Completed NCT00560066 - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Phase 4
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT04896086 - First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV, in Healthy Adults Phase 1
Completed NCT01342796 - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Phase 2
Completed NCT01344057 - Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 Phase 2
Completed NCT00903552 - Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) Phase 2
Completed NCT05827068 - A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults Phase 1/Phase 2
Completed NCT05415462 - A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Phase 3